Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orit Cohen

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Cephalalgia : an International Journal of Headache|April 19, 2018
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjectsOrit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, et al.
Drug and Alcohol Dependence|July 11, 2016
Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependenceYossi Gilgun-Sherki, Rom E Eliaz, David J McCann, et al.
Journal of Clinical Pharmacology|December 20, 2014
Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjectsOrit Cohen-Barak, Jacqueline Wildeman, Jeroen van de Wetering, et al.
Clinical Pharmacology in Drug Development|January 7, 2021
A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled SyringeIrina Cherniakov, Orit Cohen-Barak, Ryan Tiver, et al.
Journal of Clinical Psychopharmacology|June 18, 2015
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine UsersMegan J Shram, Orit Cohen-Barak, Bijan Chakraborty, et al.
Cephalalgia : an International Journal of Headache|May 18, 2021
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approachOrit Cohen-Barak, Andrijana Radivojevic, Aksana Jones, et al.
British Journal of Clinical Pharmacology|July 1, 2018
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjectsFrank Schneider, Lavi Erisson, Hooman Beygi, et al.
Journal of Forensic Sciences|February 18, 2010
Predicting phenotype from genotype: normal pigmentationRobert K Valenzuela, Miquia S Henderson, Monica H Walsh, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Cephalalgia : an International Journal of Headache|April 19, 2018
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjectsOrit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, et al.
Drug and Alcohol Dependence|July 11, 2016
Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependenceYossi Gilgun-Sherki, Rom E Eliaz, David J McCann, et al.
Journal of Clinical Pharmacology|December 20, 2014
Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjectsOrit Cohen-Barak, Jacqueline Wildeman, Jeroen van de Wetering, et al.
Clinical Pharmacology in Drug Development|January 7, 2021
A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled SyringeIrina Cherniakov, Orit Cohen-Barak, Ryan Tiver, et al.
Journal of Clinical Psychopharmacology|June 18, 2015
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine UsersMegan J Shram, Orit Cohen-Barak, Bijan Chakraborty, et al.
Cephalalgia : an International Journal of Headache|May 18, 2021
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approachOrit Cohen-Barak, Andrijana Radivojevic, Aksana Jones, et al.
British Journal of Clinical Pharmacology|July 1, 2018
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjectsFrank Schneider, Lavi Erisson, Hooman Beygi, et al.
Journal of Forensic Sciences|February 18, 2010
Predicting phenotype from genotype: normal pigmentationRobert K Valenzuela, Miquia S Henderson, Monica H Walsh, et al.
Pageof 5